This Friday morning session honors the 2021 LCGC award winners: Paul Haddad of the University of Tasmania, and the foundation director of the Australian Centre for Research on Separation Science (ACROSS); and Erik L. Regalado, of the pharmaceutical company Merck & Co.
Following a brief presentation of the two awards by Laura Bush of LCGC, the first talk will be from Lifetime Award winner Paul Haddad, at 8:40 am.
Haddad will discuss a collaborative project—among a university research center, two major pharmaceutical companies, and a scientific instrument developer— to develop a miniaturized, portable high performance liquid chromatography (HPLC) system for deployment in the pharmaceutical industry. The platform will be described in detail, together with a range of additions designed to improve ease of application and to increase detection selectivity and sensitivity.
Next, at 9:15, Emily Hilder of the University of South Australia will address the synthesis and functionalization of nanostructured porous polymer materials for analytical applications. The presentation will focus primarily on polymer-based monolithic materials for which the relatively simple preparation, robustness, high permeability to flow, mass transfer via convection and flexible chemistry has seen these materials used in a range of applications such as chromatography and as supports for synthesis, catalysis, and immobilized enzymes.
Peter Schoenmakers of the University of Amsterdam will give the third talk, at 9:50, on LC method development and optimization. Recent progress in LC method development strategies now allows systematic, computer-based development and optimization of highly complex analysis, such as comprehensive two-dimensional LC (LC×LC), leading to enormous time savings and lowering the threshold for applying LC×LC in practice.
Emerging Leader Erik Regalado of Merck will give his talk at 10:40, on advances in automated multicolumn screening combined with computer-assisted modeling for analytical and preparative chromatography of new pharmaceuticals. The screening and modeling approaches discussed here can minimize the time spent developing new analytical assays, while also facilitating method transfer to manufacturing facilities and application in regulatory settings.
Chris Welch of the Indiana Consortium for Analytical Science & Engineering (ICASE) will wrap up the session with a talk at 11:15 on high-throughput analysis to enable high-throughput experimentation in pharmaceutical process research. A personal account of the evolution of high-throughput analysis and the role that measurement science has played in enabling the success of high-throughput experimentation is presented, along with an assessment of current challenges and future prospects.
Link to the full session:
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.
Exploring The Chemical Subspace of RPLC: A Data-driven Approach
November 11th 2024Saer Samanipour from the Van ‘t Hoff Institute for Molecular Sciences (HIMS) at the University of Amsterdam spoke to LCGC International about the benefits of a data-driven reversed-phase liquid chromatography (RPLC) approach his team developed.
Pharmaceutical excipients, such as polyethylene glycol-based polymers, must be tested for the presence of ethylene oxide (EtO) and 1,4-dioxane as part of a safety assessment, according to USP Chapter <228>.